CSIMarket Company Name, Ticker, Industry, else..
 
Bluejay Diagnostics Inc  (NASDAQ: BJDX)
 
Price: $0.9720 $-0.04 -3.762%
Day's High: $0.9800000190734863 Week Perf: 14.49 %
Day's Low: $ 0.96 30 Day Perf: -9.16 %
Volume (M): 125,225 52 Wk High: $ 16.68
Volume (M$): $ 0 52 Wk Avg: $3.47
Open: $0.97 52 Wk Low: $0.82



 Market Capitalization (Millions $) 2
 Shares Outstanding (Millions) 2
 Employees 6
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -7
 Cash Flow (TTM) (Millions $) -3
 Capital Exp. (TTM) (Millions $) 0

Business Description


Bluejay Diagnostics Inc is a healthcare company that specializes in the development and production of innovative diagnostic solutions. The company focuses on creating a range of diagnostic products, including rapid diagnostic tests, point-of-care devices, and lab-based testing solutions for various medical conditions. Bluejay Diagnostics Inc aims to improve patient outcomes by delivering accurate and timely diagnostic results while also providing convenience and ease of use for healthcare professionals.


   Company Address: 360 Massachusetts Avenue Acton 1720 MA
   Company Phone Number: 327-7078   Stock Exchange / Ticker: NASDAQ BJDX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BDX   -5.47%    
IRIX   -6.85%    
LNSR   -1.77%    
LUCD   -18.61%    
MLSS   -9.13%    
OSUR   -4.82%    
• View Complete Report
   



Shares

Bluejay Diagnostics Undertakes Strategic Financial Moves: Reverse Stock Split and Successful Public Offering Amid Expanding Diagnostics Solutions

Published Wed, Nov 13 2024 10:11 PM UTC

Bluejay Diagnostics: A Strategic Shift Forward in Medical TechnologyIn a bold maneuver aimed at bolstering its market position, Bluejay Diagnostics, Inc. (NASDAQ: BJDX) has announced a significant reverse stock split of its shares at a ratio of 1-for-50, effective 12:01 a.m. Eastern Time on November 18, 2024. This decision comes in conjunction with the company s ongoing comm...
Stocks on the Move

Bluejay Diagnostics Inc Faces Challenges as Financial Performance Declines

Published Sun, Jun 30 2024 12:10 PM UTC

Bluejay Diagnostics Inc (NASDAQ: BJDX) has recently encountered a sell-off in its shares, raising concerns about the company s financial health. This article explores the reasons behind this decline, including the negative gross margin posted last year and the underperformance of Bluejay Diagnostics Inc shares compared to the overall market. We will also examine the implicat...
Financing Agreement

Bluejay Diagnostics, a medical technology company specializing in developing rapid diagnostics for critical care settings, has successfully closed a firm commitment underwritten public offering The offering is expected to generate gross proceeds of approximately $875 million for the company, before deducting underwriting discounts and other estimated expenses

Published Fri, Jun 28 2024 3:33 PM UTC

Bluejay Diagnostics, a medical technology company specializing in developing rapid diagnostics for critical care settings, has successfully closed a firm commitment underwritten public offering. The offering is expected to generate gross proceeds of approximately $8.75 million for the company, before deducting underwriting discounts and other estimated expenses.
The base...
Shares

Bluejay Diagnostics Secures $8.75 Million Funding to Drive Medical Technology Advancements

Published Thu, Jun 27 2024 12:58 PM UTC



In a recent press release, Bluejay Diagnostics, a leading medical technology company, announced the successful pricing of their underwritten public offering. With a firm commitment, the company is set to receive approximately $8.75 million in gross proceeds, signaling a major breakthrough for their development of rapid diagnostics on the innovative Symphony platfor...
Clinical Study

Elevated IL-6 Levels Predict 28-Day Mortality in Sepsis Patients Insights from the SYMON-I Pilot Study

Published Wed, Jun 26 2024 12:00 PM UTC

Interpreting IL-6 as a Predictor of Mortality in Sepsis Patients: Insights from the SYMON-I Study Sepsis, a life-threatening condition resulting from the body s dysregulated response to infection, presents a significant challenge in critical care medicine due to its high mortality rates. Early and accurate identification of patients at highest risk of mortality is crucial f...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 0.21
PEG (TTM) -

Financial Strength Current
Quick Ratio 4.53
Working Capital Ratio 4.64
Leverage Ratio (MRQ) 0.23
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -7.26 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 4.62 $
Book Value 4.53 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,211,798
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.